Fratricide-Resistant CAR-T Cells for T Cell Malignancies
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Chimeric antigen receptor (CAR)-T cell therapy for T cell malignancies is hindered by fratricide and shared antigen expression, leading to reduced efficacy and clinical benefit.
Innovation Solution
Engineering CAR-T cells to be deficient in the antigen recognized by the chimeric antigen receptor and optionally incorporating a suicide gene or blocking endogenous T cell receptor (TCR) signaling to prevent fratricide and enhance safety.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CAR-T cells are engineered to target T cell malignancies, then therapeutic efficacy against cancer is improved, but fratricide of CAR-T cells occurs due to shared antigen expression
Solution Approach 1:
The patent removes the harmful antigen from the CAR-T cell surface through gene editing, extracting the source of fratricide while preserving the cell's therapeutic function. The antigen recognized by the CAR is specifically deleted from the CAR-T cell genome, allowing the receptor to remain functional for targeting malignancies without causing self-destruction.
Solution Approach 2:
The invention creates a localized difference in antigen expression: CAR-T cells lack the target antigen on their surface while malignancy cells retain it. This local quality distinction allows selective targeting - the CAR binds to antigens on cancer cells but not on the CAR-T cells themselves, eliminating fratricide while maintaining therapeutic efficacy.
2Ease of manufacture
If CAR-T cells express the target antigen, then they can be generated from patient cells, but clinical benefit is reduced due to fratricide and shared antigen expression
Solution Approach 1:
The patent applies preliminary gene editing to remove the target antigen from patient-derived T cells before generating CAR-T cells. This preliminary action prevents the subsequent problem of fratricide and ensures that when the CAR-T cells are administered, they will not destroy themselves, thereby maintaining clinical benefit while still allowing generation from patient cells.
Solution Approach 2:
The invention converts the harmful shared antigen expression into a benefit by selectively removing it from CAR-T cells while leaving it on malignancy cells. This creates the ideal scenario where the antigen serves as a target marker for cancer cells but not for therapeutic cells, transforming the original problem into a therapeutic advantage.
3Productivity
If allogeneic CAR-T cells are used to treat malignancies, then productivity and availability are improved, but graft versus host disease occurs
Solution Approach 1:
The patent removes the T cell receptor alpha chain (TRAC) from allogeneic CAR-T cells through gene editing, extracting the component responsible for recognizing host antigens. This elimination of TRAC prevents the allogeneic CAR-T cells from attacking host tissues, thereby preventing graft versus host disease while maintaining the ability to produce off-the-shelf therapies.
Solution Approach 2:
The invention fundamentally changes the immunogenicity parameter of allogeneic CAR-T cells by knocking out TRAC expression. This parameter change renders the cells non-alloreactive, allowing them to be produced from healthy donors and administered to patients without causing graft versus host disease, thus enabling scalable productivity.
Data Source
AI summary
The present disclosure provides the use of fratricide-resistant chimeric antigen receptor T (CAR-T) cells targeting antigens expressed by T cell malignancies.